Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).
Sponsor: Juan A. Arnaiz
A PHASE4 clinical study on Acquired Immune Deficiency Syndrome Virus, this trial is ongoing. The trial is conducted by Juan A. Arnaiz and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Sep 2018 — Sep 2020 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — May 2018 [monthly]
Recruiting PHASE4
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Juan A. Arnaiz
For direct contact, visit the study record on ClinicalTrials.gov .